|
1
|
Cortes J, Kim DW, Raffoux E, Martinelli G,
Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, et al:
Efficacy and safety of dasatinib in imatinib-resistant or
-intolerant patients with chronic myeloid leukemia in blast phase.
Leukemia. 22:2176–2183. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Quintás-Cardama A, Kantarjian H, O'brien
S, Borthakur G, Bruzzi J, Munden R and Cortes J: Pleural effusion
in patients with chronic myelogenous leukemia treated with
dasatinib after imatinib failure. J Clin Oncol. 25:3908–3914. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldblatt M, Huggins JT, Doelken P, Gurung
P and Sahn SA: Dasatinib-induced pleural effusions: A lymphatic
network disorder? Am J Med Sci. 338:414–417. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nagata Y, Ohashi K, Fukuda S, Kamata N,
Akiyama H and Sakamaki H: Clinical features of dasatinib-induced
large granular lymphocytosis and pleural effusion. Int J Hematol.
91:799–807. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paydas S: Dasatinib, large granular
lymphocytosis, and pleural effusion: Useful or adverse effect? Crit
Rev Oncol Hematol. 89:242–247. 2014. View Article : Google Scholar
|
|
6
|
Laneuville P, Baccarani M, Cortes JE,
Hochhaus A, Kantarjian H, Shah NP, Bradley-Garelik MB, Zhu C and
Porkka K: Analysis of patients (pts) with chronic phase chronic
myeloid leukemia (CML-CP) who develop pleural effusion on
first-line dasatinib: Management and outcomes. J Clin Oncol.
29(Suppl): 66052011.
|
|
7
|
Kantarjian HM, Shah NP, Cortes JE,
Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipiña JJ, Kim DW,
Ogura M, et al: Dasatinib or imatinib in newly diagnosed
chronic-phase chronic myeloid leukemia: 2-year follow-up from a
randomized phase 3 trial (DASISION). Blood. 119:1123–1129. 2012.
View Article : Google Scholar
|
|
8
|
Iriyama N, Fujisawa S, Yoshida C, Wakita
H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi
K, et al: Shorter halving time of BCR-ABL1 transcripts is a novel
predictor for achievement of molecular responses in newly diagnosed
chronic-phase chronic myeloid leukemia treated with dasatinib:
Results of the D-first study of Kanto CML study group. Am J
Hematol. 90:282–287. 2015. View Article : Google Scholar
|
|
9
|
Yoshida C, Fletcher L, Ohashi K, Wakita H,
Kumagai T, Shiseki M, Matsuei K, Inokuchi K, Hatta Y, Shirasugi Y,
et al: Harmonization of molecular monitoring of chronic myeloid
leukemia therapy in Japan. Int J Clin Oncol. 17:584–589. 2012.
View Article : Google Scholar
|
|
10
|
Kumagai T, Matsuki E, Inokuchi K, Ohashi
K, Shinagawa A, Takeuchi J, Yoshida C, Okamoto S, Wakita H, Kozai
Y, et al: Relative increase in lymphocytes from as early as 1 month
predicts improved response to dasatinib in chronic-phase chronic
myelogenous leukemia. Int J Hematol. 99:41–52. 2014. View Article : Google Scholar
|
|
11
|
Kantarjian H, Shah NP, Hochhaus A, Cortes
J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, et al:
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic
myeloid leukemia. N Engl J Med. 362:2260–2270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim D, Goh HG, Kim SH, Cho BS and Kim DW:
Long-term pattern of pleural effusion from chronic myeloid leukemia
patients in second-line dasatinib therapy. Int J Hematol.
94:361–371. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Latagliata R, Breccia M, Fava C, Stagno F,
Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M,
Cavazzini F, et al: Incidence, risk factors and management of
pleural effusions during dasatinib treatment in unselected elderly
patients with chronic myelogenous leukaemia. Hematol Oncol.
31:103–109. 2013. View
Article : Google Scholar
|
|
14
|
Eskazan AE, Eyice D, Kurt EA, Elverdi T,
Yalniz FF, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z,
Ferhanoglu B, et al: Chronic myeloid leukemia patients who develop
grade I/II pleural effusion under second-line dasatinib have better
responses and outcomes than patients without pleural effusion. Leuk
Res. 38:781–787. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Porkka K, Khoury HJ, Paquette RL, Matloub
Y, Sinha R and Cortes JE: Dasatinib 100 mg once daily minimizes the
occurrence of pleural effusion in patients with chronic myeloid
leukemia in chronic phase and efficacy is unaffected in patients
who develop pleural effusion. Cancer. 116:377–386. 2010. View Article : Google Scholar
|
|
16
|
Wang X, Hochhaus A, Kantarjian HM, et al:
Dasatinib pharmacokinetics and exposure-response (E-R):
Relationship to safety and efficacy in patients (pts) with chronic
myeloid leukemia (CML). J Clin Oncol. 26(Suppl): 35952008.
|
|
17
|
Shah NP, Kantarjian HM, Kim DW, Réa D,
Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ,
Charbonnier A, et al: Intermittent target inhibition with dasatinib
100 mg once daily preserves efficacy and improves tolerability in
imatinib-resistant and -intolerant chronic-phase chronic myeloid
leukemia. J Clin Oncol. 26:3204–3212. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Lavallade H, Punnialingam S, Milojkovic
D, Bua M, Khorashad JS, Gabriel IH, Chaidos A, Olavarria E, Goldman
JM, Apperley JF, et al: Pleural effusions in patients with chronic
myeloid leukaemia treated with dasatinib may have an
immune-mediated pathogenesis. Br J Haematol. 141:745–747. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mustjoki S, Ekblom M, Arstila TP, Dybedal
I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M,
Kovanen P, Laurinolli T, et al: Clonal expansion of T/NK-cells
during tyrosine kinase inhibitor dasatinib therapy. Leukemia.
23:1398–1405. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kreutzman A, Juvonen V, Kairisto V, Ekblom
M, Stenke L, Seggewiss R, Porkka K and Mustjoki S: Mono/oligoclonal
T and NK cells are common in chronic myeloid leukemia patients at
diagnosis and expand during dasatinib therapy. Blood. 116:772–782.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim DH, Kamel-Reid S, Chang H, Sutherland
R, Jung CW, Kim HJ, Lee JJ and Lipton JH: Natural killer or natural
killer/T cell lineage large granular lymphocytosis associated with
dasatinib therapy for Philadelphia chromosome positive leukemia.
Haematologica. 94:135–139. 2009. View Article : Google Scholar :
|
|
22
|
Chuah CT, Nakamae H, Shen ZX,
Bradley-Garelik MB and Kim DW: Efficacy and safety of dasatinib
versus imatinib in the East Asian subpopulation of the DASISION
trial of newly diagnosed chronic myeloid leukemia in chronic phase.
Leuk Lymphoma. 55:2093–2100. 2014. View Article : Google Scholar :
|
|
23
|
Fujisawa S, Nakamae H, Ogura M, Ishizawa
K, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K,
Tanimoto M, et al: Efficacy and safety of dasatinib versus imatinib
in Japanese patients with newly diagnosed chronic-phase chronic
myeloid leukemia (CML-CP): Subset analysis of the DASISION trial
with 2-year follow-up. Int J Hematol. 99:141–153. 2014. View Article : Google Scholar
|
